Get the Stockscreener App
6.35
1.55%
-0.10
After Hours:
6.26
-0.09
-1.42%
Immuneering Corp stock is traded at $6.35, with a volume of 1.30M.
It is down -1.55% in the last 24 hours and up +6.54% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$6.45
Open:
$6.2
24h Volume:
1.30M
Relative Volume:
0.70
Market Cap:
$263.97M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-3.3598
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
-7.84%
1M Performance:
+6.54%
6M Performance:
+403.97%
1Y Performance:
+227.32%
1-Day Range:
$6.0002
$6.66
1-Week Range:
$6.0002
$7.57
52-Week Range:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
6.35 | 407.89M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Is Immuneering Corporation stock poised for growthJuly 2025 Highlights & Real-Time Buy Signal Notifications - newser.com
Immuneering Corporation (NASDAQ:IMRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Combining machine learning predictions for Immuneering CorporationJuly 2025 Movers & Precise Swing Trade Entry Alerts - newser.com
What data driven models say about Immuneering Corporation’s futureWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
How Immuneering Corporation stock compares to growth peersFed Meeting & Advanced Technical Analysis Signals - newser.com
Is Immuneering Corporation stock undervalued vs historical averages2025 Short Interest & Growth Focused Entry Point Reports - newser.com
Immuneering Corp. Shines in Positive Earnings Call - TipRanks
What momentum indicators show for Immuneering Corporation stockWeekly Stock Report & High Return Trade Guides - newser.com
Can Immuneering Corporation stock reach $100 price targetWeekly Trend Report & Consistent Income Trade Ideas - newser.com
Immuneering rises after smaller-than-expected Q3 loss - TradingView
Immuneering Corp. Reports Strong Q3 2025 Progress - TipRanks
Earnings call transcript: Immuneering Q3 2025 emphasizes cash boost and trial progress - Investing.com Nigeria
Immuneering Corporation Reports 86% Overall Survival in Pancreatic Cancer Patients and Secures $225 Million in Financing - Quiver Quantitative
What indicators show strength in Immuneering CorporationWeekly Gains Report & Stepwise Entry/Exit Trade Alerts - newser.com
A look into Immuneering Corp (IMRX)’s deeper side - setenews.com
Does Immuneering Corporation qualify in momentum factor screeningJuly 2025 Earnings & Weekly Top Gainers Trade List - newser.com
A Preview Of Immuneering's Earnings - Benzinga
Trend analysis for Immuneering Corporation this weekWeekly Market Report & Low Drawdown Momentum Ideas - newser.com
Immuneering (IMRX) to Release Earnings on Wednesday - Defense World
How to read the order book for Immuneering CorporationJuly 2025 Chart Watch & Risk Adjusted Buy and Sell Alerts - newser.com
Will Immuneering Corporation stock attract more institutional investors2025 Year in Review & High Accuracy Swing Entry Alerts - Fundação Cultural do Pará
Top chart patterns to watch in Immuneering CorporationForecast Cut & Smart Money Movement Alerts - newser.com
Can Immuneering Corporation stock sustain institutional interest2025 Sector Review & Proven Capital Preservation Methods - newser.com
Immuneering Corporation (IMRX) stock forecast and price target - Yahoo! Finance UK
Immuneering (IMRX) Expected to Announce Earnings on Wednesday - MarketBeat
Why Immuneering Corporation stock is recommended by analystsWeekly Trend Summary & AI Powered Market Trend Analysis - newser.com
How Immuneering Corporation stock valuations compare to rivalsJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Will Immuneering Corporation stock outperform value stocks2025 Historical Comparison & AI Forecasted Entry/Exit Points - newser.com
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 - The Manila Times
Has Immuneering Corporation formed a bullish divergencePortfolio Return Report & Growth-Oriented Investment Plans - newser.com
Best data tools to analyze Immuneering Corporation stockAnalyst Upgrade & Free High Accuracy Swing Entry Alerts - newser.com
Is Immuneering Corporation stock ready for a breakoutJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
Is Immuneering Corporation stock attractive for growth ETFsDividend Hike & High Accuracy Trade Alerts - Fundação Cultural do Pará
Is Immuneering Corporation stock positioned well for digital economyGap Up & Entry Point Strategy Guides - newser.com
Can Immuneering Corporation rally from current levelsQuarterly Investment Review & Real-Time Market Sentiment Alerts - newser.com
Can momentum traders help lift Immuneering CorporationPortfolio Value Summary & Stepwise Swing Trade Plans - newser.com
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):